2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Metabolic Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1380 TNF-α/NF-κB signaling imprints dysfunctional immune memory in cystic fibrosis

Rubia Isler Mancuso, PhD, Cassia Lisboa Braga2, Evrett Thompson, PhD3, Ravindra Gudneppanavar4, Hasan H Oez5, Ping-Xia Zhang, MD, PhD6, Pamela H Huang7, Thomas Murray8, Marie E Egan9, Emanuela M Bruscia10, Diane Krause, MD, PhD11
1 Yale University, New Haven, United States
2 Yale University, New Haven, United States
3 Yale University, New Haven, United States
4 Yale University, New Haven, United States
5 Yale University, New Haven, United States
6 Yale University, New Haven, United States
7 Yale University, New Haven, United States
8 Yale University, New Haven, United States
9 Yale University, New Haven, United States
10 Yale University, New Haven, United States
11 Yale University, New Haven, United States

Introduction: Epigenetic reprogramming of hematopoietic stem and progenitor cells (HSPCs) enables trained immunity (TI), which boosts host defense. However, chronic inflammation may instead lead to maladaptive immune memory with hyperinflammation. Although cystic fibrosis is not traditionally considered a hematological disorder, CF is a disease of persistent inflammation and dysfunctional myeloid cells. We tested whether chronic inflammation permanently reprograms CF HSPCs and whether TNF-α is sufficient to reproduce this phenotype.
Methods: As a model of chronic inflammation, wild-type (WT) and Cftr knockout (CF) mice were exposed to nebulized LPS 3 times weekly for 5 wks and analyzed at baseline (T0), 24 hrs after the final dose (T1), or after a 6-wk recovery (T2; n=3/group). Flow cytometry, serum cytokine assessment, scRNA-seq, ATAC-seq, phagocytosis assays, and bone marrow (BM) transplantation were performed. ATAC-seq was done on sorted Lin⁻Sca1⁺Kit⁺Flt3-CD48-CD150+ HSCs and Lin-Sca-Kit+CD41-FcgR+ GMPs. CD45.2⁺ WT and CF BM from T0 or T2 mice was transplanted into lethally irradiated CD45.1⁺ WT recipients, and donor-derived HSPCs were analyzed 12 weeks later. To evaluate TNF-α signaling, WT mice received TNF-α (40 ng/g/day i.p.) for 28 days.
Results: At baseline, CF BM has increased frequencies of CD41⁺ LT-HSC (WT 0.25% vs CF 0.55%, p<0.05 of Lin- cells) and GMPs (WT 9.93% versus CF 12.96%, p<0.05) that remained elevated at T2. LSK scRNA-seq at T0 and T2 each had DEGs strongly enriched for TNF-α/NF-kB signaling, and CF mice had elevated serum TNF-α (WT [5.35 pg/ml] vs CF [13.66 pg/mL], p<0.05). Chronic LPS exposure induced protective TI in WT mice, enhancing lung bacterial clearance after Pseudomonas aeruginosa (PA) re-challenge. In contrast, CF mice develop pathogenic TI with an exaggerated and ineffective inflammatory response. In vitro, macrophages (Mφ) derived from WT T2 HSPCs showed a 46% increase in phagocytosis vs WT T0 (p<0.05) and at least a 40% decrease in inflammatory cytokines consistent with TI. In contrast, Mφ from CF T2 HSPCs showed a 33% reduction in phagocytosis (p<0.05) and no decrease in inflammatory cytokines, indicating hyperinflammatory but dysfunctional immune progeny. In contrast, ATAC-seq showed no significant differences between WT and CF HSPCs at T0. After chronic LPS exposure (T2), however, CF HSPCs acquired extensive chromatin remodeling differentially accessible regions (DAR for T0 vs T2: WT= 619 vs CF= 3,043) with CF peaks enriched (adj P value 1 x 10-9) for TNF-α signaling and inflammatory response. In vivo post-transplant, WT-T2 donor derived HSCs showed minimal chromatin remodeling, whereas CF-T2 donor derived HSCs retained extensive DARs enriched for TNF-α/NF- κB signaling, demonstrating durable epigenetic reprogramming. Given the persistent GMP expansion at T2 together with a marked neutrophilic infiltration following PA infection in CF, we assessed for epigenetic reprograming of GMPs. In WT GMP, 1,872 were more accessible at T2 and were enriched for inflammatory response, leukocyte activation and cytokine production. CF GMPs had 2,5X more (4,631) DAR at genes enriched for cell killing and metabolic pathways. Many (~60%) regions that remained open in CF HSPCs at T2 were also accessible in T0 CF GMPs, indicating that HSC chromatin changes are associated with myeloid differentiation, consistent with myeloid-skewed hematopoiesis. Prompted by the elevated TNF-α signaling in naïve CF HSCs and its epigenetic reinforcement after chronic LPS exposure, we evaluated whether systemic TNF-α is sufficient to alter HSC and trigger maladaptive TI. Chronic TNF-α exposure reproduced key CF features, including increased LSK, CD41+LT-HSC, MPP2/3 and circulating monocytes. Also, Mφ from TNF-α-treated mice failed to mount an enhanced phagocytic and inflammatory response consistent with failed TI in T2 CF Mφ.
Conclusions: CF-associated chronic inflammation induces persistent epigenetic reprogramming in HSCs that extends to GMPs, establishing durable maladaptive TI. CF HSPCs fail to develop protective trained immunity and instead acquire maladaptive immune memory that is phenocopied by chronic TNF-α exposure identifying sustained TNF-α signaling as a major driver of this process.

Rubia Isler Mancuso, PhD: No relevant conflicts of interest to declare.